Early discontinuation of a hypomethylating agent was associated with an increase in economic burden for those with refractory anemia with excess blasts, a diagnosis that overlaps with high-risk myelodysplastic syndrome.
Investigators have identified an association between the diagnosis and care of older patients with multiple myeloma and substantial financial burden on Medicare.
A real-world study found patients with relapsed/refractory multiple myeloma who were triple-class exposed had higher healthcare costs and unmet treatment needs.
Survival among patients with multiple myeloma appears to be influenced by factors such as socioeconomic status and treatment facility type.
A synthesis of P-values across 16 studies in different global regions found that socioeconomic status continues to be a significant prognostic factor of overall survival for patients with multiple myeloma.